SCYNEXIS Announces Oral Presentation of Data from Ibrexafungerp Phase 2b DOVE Study at the 3rd ISIDOG Congress

Stock Information for SCYNEXIS Inc.

Loading

Please wait while we load your information from QuoteMedia.